3,4-Methylenedioxymethamphetamine (MDMA), but not morphine, alters APP processing in the rat brain

Area of Science:

• Neuroscience
• Pharmacology
• Molecular Biology

Background:

• Drug abuse, including opioids and MDMA (ecstasy), can impair cognitive functions.
• The precise molecular mechanisms driving drug-induced neurodegeneration are not fully understood.
• Amyloid precursor protein (APP) processing is central to Alzheimer's disease pathogenesis.

Purpose of the Study:

• To investigate the effects of chronic morphine and MDMA administration on APP expression and processing in vivo.
• To determine if these drugs alter key molecules involved in Alzheimer's disease pathways.

Main Methods:

• Pilot study involving chronic in-vivo administration of morphine (10 mg/kg) or MDMA (1 mg/kg) to rats.
• Analysis of APP, beta-secretase (BACE), and APP mRNA levels in brain cortex cytosolic fractions.

Main Results:

• MDMA treatment significantly reduced cytosolic APP production.
• MDMA increased both BACE protein levels and APP mRNA expression by 25% and 108%, respectively.
• Chronic morphine treatment did not alter APP or BACE protein levels or APP mRNA production.

Conclusions:

• Chronic MDMA (ecstasy) use, unlike morphine, may harm the brain through a novel mechanism involving altered APP expression and processing.
• These findings suggest a potential link between ecstasy use and neurodegenerative pathways, possibly related to Alzheimer's disease mechanisms.